ArticlePloS one2014
Inhibition of nucleotide biosynthesis potentiates the antifungal activity of amphotericin B.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Chitosan nanoparticles loaded with ribavirin, carboplatin, and thyme oil downregulate SNQ2, ERG11, CDR1, and MDR1 in Candida strains.Scientific reports · 2025Article
- Discovery of CONature microbiology · 2024Article
- Comparative analysis of the biological characteristics and mechanisms of azole resistance of clinicalFrontiers in microbiology · 2023Article
- Antifungal Activity of Sodium New Houttuyfonate AgainstFrontiers in microbiology · 2022Article
- Drug repurposing strategies in the development of potential antifungal agents.Applied microbiology and biotechnology · 2021Review
- Synthetic Derivatives of Ciclopirox are Effective Inhibitors ofACS omega · 2021Article
- Antifungal Drug Repurposing.Antibiotics (Basel, Switzerland) · 2020Article
- In vitro activity of EDTA and TOL-463 against Neisseria gonorrhoeae.Diagnostic microbiology and infectious disease · 2019Article
- Synergistic and antagonistic effects of immunomodulatory drugs on the action of antifungals againstPeerJ · 2018Article
- Purine Acquisition and Synthesis by Human Fungal Pathogens.Microorganisms · 2017Review
- Troponoids Can Inhibit Growth of the Human Fungal Pathogen Cryptococcus neoformans.Antimicrobial agents and chemotherapy · 2017Article
- Inhibition of nucleic acid biosynthesis makes little difference to formation of amphotericin B-tolerant persisters in Candida albicans biofilm.Antimicrobial agents and chemotherapy · 2015Article
- Inhibitors of amino acids biosynthesis as antifungal agents.Amino acids · 2015Review
- cspA influences biofilm formation and drug resistance in pathogenic fungus Aspergillus fumigatus.BioMed research international · 2015Article
- The role of the de novo pyrimidine biosynthetic pathway in Cryptococcus neoformans high temperature growth and virulence.Fungal genetics and biology : FG & B · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The polyene antifungal agent Amphotericin B exhibits potent and broad spectrum fungicidal activity. However, high nephrotoxicity can hinder its administration in resource poor settings. Quantification of early fungicidal activity in studies of HIV patients with cryptococcosis demonstrate that 5-Fluorocytosine therapy in combination with Amphotericin B results in faster clearance than with Amphotericin B alone. In vitro synergy between the two drugs has also been reported but the mechanism by which 5-Fluorocytosine synergizes with Amphotericin B has not been delineated. In this study we set out to investigate the effect of genetic mutation or pharmacologic repression of de novo pyrimidine and purine biosynthesis pathways on the Amphotericin B susceptibility of Cryptococcus neoformans. We demonstrate that a ura- derivative of wild type Cryptococcus neoformans strain H99 is hypersensitive to Amphotericin B. This sensitivity is remediated by re-introduction of a wild type URA5 gene, but not by addition of exogenous uracil to supplement the auxotrophy. Repression of guanine biosynthesis by treatment with the inosine monophosphate dehydrogenase inhibitor, mycophenolic acid, was synergistic with Amphotericin B as determined by checkerboard analysis. As in Cryptococcus neoformans, a ura(-) derivative of Candida albicans was also hypersensitive to Amphotericin B, and treatment of Candida albicans with mycophenolic acid was likewise synergistic with Amphotericin B. In contrast, neither mycophenolic acid nor 5-FC had an effect on the Amphotericin B susceptibility of Aspergillus fumigatus. These studies suggest that pharmacological targeting of nucleotide biosynthesis pathways has potential to lower the effective dose of Amphotericin B for both C. neoformans and C. albicans. Given the requirement of nucleotide and nucleotide sugars for growth and pathogenesis of Cryptococcus neoformans, disrupting nucleotide metabolic pathways might thus be an effective mechanism for the development of novel antifungal drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.